<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627625</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-07-000025</org_study_id>
    <nct_id>NCT02627625</nct_id>
  </id_info>
  <brief_title>Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products</brief_title>
  <official_title>Phase I Randomised, Five-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Three Test Products With Two Reference Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the absorption of three different inhalation products
      with the reference products in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects will be enrolled and will receive single doses of 3 test inhalation products
      and two reference inhalation products according to a five-period cross-over design. Plasma
      tiotropium levels will be measured pre-dose and over 8 hours post-dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>8 hours</time_frame>
    <description>noncompartmental analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 hours</time_frame>
    <description>reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration vs Time Curve (AUC)</measure>
    <time_frame>8 hours</time_frame>
    <description>trapezoidal rule</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>test product A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test product B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test product C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial product D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>commercial product E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>4 inhalations</description>
    <arm_group_label>test product A</arm_group_label>
    <arm_group_label>test product B</arm_group_label>
    <arm_group_label>test product C</arm_group_label>
    <arm_group_label>Commercial product D</arm_group_label>
    <arm_group_label>commercial product E</arm_group_label>
    <other_name>Spiriva Respimat</other_name>
    <other_name>Spiriva Handihaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteer

          -  Willing and able to give informed consent

          -  Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing
             foods and beverages for 24 hours prior to reporting to clinic

          -  Subjects must agree to use an adequate method of contraception from admission through
             12 weeks after last administration

        Exclusion Criteria:

          -  Evidence or history of clinically significant abnormalities or disease or chronic
             respiratory disorders

          -  Any presence or history of a clinically significant allergy including any adverse
             reaction to study drug

          -  History of drug or alcohol abuse within the past 2 years

          -  Smoked tobacco within the past 6 months or have a history of more than 10- pack years
             (number of packs smoked per day x number of years smoked)

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Have received any prescription medication within 4 weeks or investigational medication
             within 12 weeks of study (exception: contraceptives are permitted)

          -  Have received any non-prescription medication within 14 days prior to dosing
             (exception: paracetamol use within 2 days)

          -  Upper respiratory tract infection (excluding otitis media) within 14 days of the first
             study day, or lower respiratory tract infection within the last 3 months

          -  If female, nursing, lactating or pregnant

          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = Â½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pui Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical Ltd</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inhalation</keyword>
  <keyword>anticholinergic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>summary data will be available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

